Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, ...
ETF Daily News6d
abrdn plc Has $4.51 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
and Bardet-Biedl and Alström syndrome. Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts ...
pharmaphorum3d
The biggest challenges facing rare disease pharma – and how the industry can tackle them
with a drug now in Phase 2 to treat the fibrosis element of Alström Syndrome as a result of such interaction. GlobalData’s analysis ultimately says that orphan drugs face an “uphill battle ...
Yahoo Finance2d
Rhythm Pharmaceuticals, Inc. (RYTM)
After hours: February 13 at 5:40:21 PM EST Loading Chart for RYTM ...